OTHER INFORMATION
−Removed: Description of Exhibit
−Removed: Certificate of Amendment to Amend and Restated Certificate of Incorporation of Trovagene, Inc.
+Added: Number Description of Exhibit
+Added: 3.1 Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 13, 2020)
+Added: 4.1 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 13, 2020).
+Added: 4.2 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 27, 2020).
+Added: 4.3 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 16, 2020).
+Added: 10.1 Stock and Warrant Subscription Agreement entered into as of May 8, 2020 by and between, Cardiff Oncology, Inc.
+Added: and POC Capital, LLC.
(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 13, 2020)
−Removed: Securities Purchase Agreement, dated March 30, 2020, by and between Trovagene, Inc.
−Removed: and the Purchaser.
−Removed: (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 31, 2020)
−Removed: Form of Series I Pre-Funded Warrant (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 31, 2020)
−Removed: Form of Series J Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March 31, 2020)
−Removed: Securities Purchase Agreement, dated April 9, 2020, by and between Trovagene, Inc.
−Removed: and the Purchaser.
−Removed: (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 10, 2020)
−Removed: Form of Series K Pre-Funded Warrant (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on April 10, 2020)
−Removed: Form of Series L Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 10, 2020)
+Added: 10.2 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on May 13, 2020)
+Added: 10.3 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on May 19, 2020)
+Added: 10.4 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 27, 2020)
+Added: 10.5 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 16, 2020)
31.1 Certification of Principal Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Exchange Act.
2 unchanged sentences
32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema
−Removed: XBRL Taxonomy Extension Calculation Linkbase
−Removed: XBRL Taxonomy Extension Labels Linkbase
−Removed: XBRL Taxonomy Extension Presentation Linkbase
−Removed: XBRL Taxonomy Extension Definition Linkbase
+Added: 101.INS Inline XBRL Instance Document
+Added: 101.SCH Inline XBRL Taxonomy Extension Schema
+Added: 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
+Added: 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase
+Added: 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
+Added: 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase
+Added: 104 Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 is formatted in Inline XBRL
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: TROVAGENE, INC.
−Removed: /s/ Thomas Adams
+Added: CARDIFF ONCOLOGY, INC.
+Added: August 11, 2020 By:
+Added: /s/ Mark Erlander
+Added: Mark Erlander
Chief Executive Officer
−Removed: TROVAGENE, INC.
+Added: CARDIFF ONCOLOGY, INC.
+Added: August 11, 2020 By:
/s/ Brigitte Lindsay
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.